The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pneumonitis (ILD), acute and/or severe (may cause ARDS)
Publications
Diagnosis and management of interstitial pneumonitis associated with interferon therapy for chronic hepatitis C.
World journal of gastroenterology 2010 Sep 21;16;4394-9 — 2010 Sep 21 — 4394-9
Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature.
Digestive diseases and sciences 2010 Mar;55;579-85 — 2010 Mar — 579-85
Adult respiratory distress syndrome after treatment with pegylated interferon alpha-2a and ribavirin.
Heart & lung : the journal of critical care 2008 Mar-Apr;37;153-6 — 2008 Mar-Apr — 153-6
Severe interstitial pneumonitis secondary to pegylated interferon alpha-2b and ribavirin treatment of hepatitis C infection.
Digestive diseases and sciences 2004 Nov-Dec;49;1966-70 — 2004 Nov-Dec — 1966-70
Alpha-interferon induced severe pneumonitis.
Journal of toxicology. Clinical toxicology 1997;35;113-4 — 1997 — 113-4
Pneumonitis associated with natural and recombinant interferon alfa therapy for chronic hepatitis C.
Chest 1994 Mar;105;939-41 — 1994 Mar — 939-41